Regeneron Pharmaceuticals (REGN) has experienced a notable fluctuation in the bio-tech market. The firm hit a new 52-week low and experienced a 15.5% decrease in stock value year to date, with shares sold in large quantities by entities such as Franklin Resources and Geode Capital Management. Despite these challenges, REGN's odronextamab reported a 100% response rate in a lymphoma clinical trial, suggesting potential for future growth. Various investment firms have bought significant shares in REGN including Oddo BHF Asset Management Sas and World Investment Advisors LLC. Although the company declined in Q3, the financials suggest strength underlying this temporary setback. Toronto Dominion Bank has increased its stock holdings with REGN, affirming its position as an attractive investment. Additionally, REGN showed high earnings growth and continues to dominate the market with a promising portfolio.
Regeneron Pharmaceuticals REGN News Analytics from Sat, 08 Jun 2024 07:00:00 GMT to Sat, 14 Dec 2024 16:06:25 GMT -
Rating 2
- Innovation 7
- Information 4
- Rumor -2
